Within 3 months, there have been changes in the executives of 90 pharmaceutical companies!

On the evening of March 7, Guoxin Health announced that due to job changes, the company's chief accountant Shen Zhiguo applied to resign as the company's chief accountant
.
After Shen Zhiguo resigned from the above-mentioned positions, he will no longer serve in the company and its holding subsidiaries
.
At the same time, the company's board of directors agreed to appoint Wang Wenchang as the company's chief accountant, and the term of office is the same as that of the tenth board of directors of the company
.
On the same day, Shandong Pharmaceutical Glass issued an announcement that the company's board of directors recently received a resignation report from Jiang Min, an independent director
.
Jiang Min has served as an independent director of the company for 6 consecutive years.
According to relevant regulations, Jiang Min applied to the company's board of directors to resign as an independent director of the company and to hold relevant positions in various special committees of the company's board of directors
.
After resigning, Jiang Min does not hold any position in the company
.
Dorui Medicine also issued an announcement stating that due to personal reasons, the company's deputy general manager, Mr.
Yao Hongjun, applied to resign from his position as deputy general manager, and he would not hold other positions in the company after resignation
.
Not long ago, Mr.
Van der Hua, one of the other core personnel of Doray Medicine, also resigned from relevant positions due to personal reasons, and recently went through the resignation procedures
.
After leaving, Mr.
Van der Waal will not hold any position in the company
.
On March 3, BeiGene issued an announcement stating that Jane Huang (Huang Weijuan), a company executive and core technician, is considering applying for resignation in the near future due to personal career planning, and will officially resign as the company’s chief hematology on April 3, 2022 local time in the United States Medical officer post
.
After resigning, Huang Weijuan will continue to work in BeiGene as a consultant until November 14, 2022 or other dates to be negotiated by the two parties to ensure the smooth progress and smooth transition of related R&D work
.
According to incomplete statistics in the industry, excluding the resignation of the acting board secretary and the general election of the board of directors, in the three months from the beginning of 2022 to the present, nearly 90 senior executives of A-share pharmaceutical companies have changed, involving more than 120 related medical personnel.
, among which there are many positions such as chairman, deputy general manager, vice president, and core technical personnel
.
It is worth mentioning that the core technical personnel master the company's core technical resources, so it is self-evident that it is important for pharmaceutical companies, especially innovative pharmaceutical companies that focus on R&D.

.
The industry pointed out that the departure of the core technical personnel of a pharmaceutical company will have a certain impact on the company's scientific research strength and research and development progress, and is not conducive to maintaining the company's competitive position in the industry
.
However, since the beginning of this year, a large number of core technicians of pharmaceutical companies have reported resignation information, including BeiGene, Chengdu Pioneer, Jiangsu Nuotai Aosino,
etc.
Among them, the above-mentioned BeiGene, the company's core technicians quickly attracted the attention of the industry after the departure of the company's core technicians.
Affected by this, BeiGene's stock price fell 6.
20% on March 4
.
On February 12, BeiGene announced that the company's core technical staff, Dr.
Ben Yong, applied to the company for resignation in August last year, and he will no longer serve as the company's chief medical officer of immuno-oncology from February 9, 2022.
job title
.
Recently, BeiGene has also received a regulatory letter from the Shanghai Stock Exchange, and the Shanghai Stock Exchange has put forward requirements for changes in the company's core technical personnel
.
In this regard, BeiGene explained from six aspects, saying that Huang Weijuan's departure this time will not have a significant adverse impact on the company's core product research and development
.
The company also stated that it will continue to further maintain the stability of the existing R&D team and core technical personnel by providing competitive salary levels, equity incentive plans and comprehensive employee benefit plans
.
The company will also continue to improve the construction of the R&D team through various means such as market recruitment and third-party recommendation, and reserve talents for the continuous expansion of the company's product pipeline and indications and the promotion of commercial scale
.
From the perspective of the industry, the environment of the pharmaceutical industry has changed in recent years, and the frequent changes in personnel within pharmaceutical companies are expected
.
However, for pharmaceutical companies, how to attract and retain talents is an urgent problem that needs to be solved.
Only by preparing sufficient backbone and backup forces can they gain a firm foothold in the future pharmaceutical arena and ride the wind and waves
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.